
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines has a positive growth outlook primarily driven by the anticipated revenue increase from the upcoming launches of zanidatamab and tarlatamab in China, in addition to ongoing revenue growth from established products like Xgeva and Kyprolis. The company’s core drug, Brukinsa, along with promising clinical outcomes in lymphoma, where response rates are around 50%, is expected to contribute significantly to revenues, potentially adding approximately $650 million by 2034. Furthermore, BeOne's innovative strategies with next-generation approaches, such as sonro and ‘673, are positioned to support continued topline growth despite potential pricing pressures in the market.
Bears say
BeOne Medicines faces a negative outlook primarily due to the slower than expected uptake of its commercial products, particularly the core drug Brukinsa, which accounts for over 60% of the company's revenue. Additionally, the company's pipeline suffers from potential failures in expanding indications, including the unsuccessful solid tumor initiative and drug candidates such as sonrotoclax and '673, which further jeopardize future growth. Compounding these challenges, historical revenue misses in the second half of previous years raise concerns regarding the sustainability and reliability of Brukinsa's sales going forward.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares